What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Gene
His primary areas of investigation include Internal medicine, Breast cancer, Cancer research, Oncology and Cancer.
His Internal medicine study frequently draws connections between related disciplines such as Endocrinology.
His Breast cancer research incorporates elements of Surgery, Gastroenterology, Hazard ratio, Antibody and Adjuvant therapy.
His Cancer research study also includes
- Pathology, which have a strong connection to Metastasis, Breast carcinoma and Epidermal growth factor receptor,
- Estrogen receptor that connect with fields like Tamoxifen.
Masakazu Toi combines subjects such as Neoadjuvant therapy, Taxane, Metastatic breast cancer, Randomized controlled trial and Gynecology with his study of Oncology.
His work is dedicated to discovering how Cancer, Chemotherapy are connected with Apoptosis and other disciplines.
His most cited work include:
- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 (1828 citations)
- Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation (668 citations)
- Nuclear factor-κB inhibitors as sensitizers to anticancer drugs (651 citations)
What are the main themes of his work throughout his whole career to date?
Masakazu Toi mainly focuses on Breast cancer, Internal medicine, Oncology, Cancer and Cancer research.
He works mostly in the field of Breast cancer, limiting it down to concerns involving Pathology and, occasionally, Mammary gland.
Masakazu Toi combines topics linked to Endocrinology with his work on Internal medicine.
His Oncology research integrates issues from Taxane, Clinical trial, Phases of clinical research, Fulvestrant and Adjuvant therapy.
His study in Cancer research is interdisciplinary in nature, drawing from both Cancer cell, Cell, Cell culture and Immunology.
Masakazu Toi has included themes like Cyclophosphamide and Anthracycline in his Docetaxel study.
He most often published in these fields:
- Breast cancer (61.03%)
- Internal medicine (54.94%)
- Oncology (44.11%)
What were the highlights of his more recent work (between 2018-2021)?
- Breast cancer (61.03%)
- Internal medicine (54.94%)
- Oncology (44.11%)
In recent papers he was focusing on the following fields of study:
The scientist’s investigation covers issues in Breast cancer, Internal medicine, Oncology, Cancer and Metastatic breast cancer.
His Breast cancer research incorporates themes from Interim analysis, Cancer research, Clinical endpoint, Radiology and Subgroup analysis.
In his study, Aromatase inhibitor and Quality of life is inextricably linked to Placebo, which falls within the broad field of Internal medicine.
His research integrates issues of Taxane, Phases of clinical research, Neutropenia, Palbociclib and Letrozole in his study of Oncology.
The Cancer study combines topics in areas such as Proportional hazards model and Cohort study.
The various areas that he examines in his Metastatic breast cancer study include Progressive disease and Nivolumab.
Between 2018 and 2021, his most popular works were:
- The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial (173 citations)
- MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. (102 citations)
- Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE) (49 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
His main research concerns Internal medicine, Breast cancer, Oncology, Metastatic breast cancer and Pertuzumab.
His studies link Placebo with Internal medicine.
The concepts of his Breast cancer study are interwoven with issues in Regimen, Cancer research and Randomized controlled trial.
His work deals with themes such as Cancer, Endocrine therapy, Tolerability and Chemotherapy, which intersect with Oncology.
His studies examine the connections between Pertuzumab and genetics, as well as such issues in Adjuvant therapy, with regards to Placebo-controlled study and Standard of care.
His studies in Trastuzumab integrate themes in fields like Taxane and Phases of clinical research.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
